Janux Therapeutics (JANX) News Today

TD Asset Management Inc bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 19,800 shares of the company's stock, valued at approx

Bank of New York Mellon Corp boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 136.3% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,027 shares of the company's stock after acquiring

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the completion of the sale, the insider now directly owns 7,000 shares in the company, valued at $296,310. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Janux Therapeutics (NASDAQ:JANX) Shares Up 4.9%

Candriam S.C.A. increased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 40.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,004 shares of the company's stock after

Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $43.71

Stifel Nicolaus started coverage on shares of Janux Therapeutics in a report on Friday. They issued a "buy" rating and a $70.00 price target for the company.

Ovata Capital Management Ltd lessened its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 50.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,000 shares of the company's stock after

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) was the recipient of a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling 3,250,000 shares, a decrease of 11.2% from the July 31st total of 3,660,000 shares. Approximately 8.6% of the shares of the company are sold short. Based on an average trading volume of 681,000 shares, the days-to-cover ratio is currently 4.8 days.

Janux Therapeutics (NASDAQ:JANX) Stock Price Up 5.3%

Janux Therapeutics (NASDAQ:JANX) Stock Price Down 3.8%

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Research analysts at HC Wainwright reduced their Q3 2024 earnings per share estimates for shares of Janux Therapeutics in a report released on Monday, August 19th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating t

SG Americas Securities LLC acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 34,664 shares of the company's stock,

Janux Therapeutics (NASDAQ:JANX) Trading 4.5% Higher

Price T Rowe Associates Inc. MD purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 19,596 shares of the company's stock, valued a

Scotiabank decreased their price target on Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating for the company in a research note on Friday.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The company's revenue for the quarter was up 709.1% compared to the same quarter last year.

Cantor Fitzgerald restated an "overweight" rating and set a $100.00 target price on shares of Janux Therapeutics in a research report on Thursday.

Vanguard Group Inc. boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 38.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,357,960 shares of the company's stock after purchasing

Virtu Financial LLC bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 16,183 shares of the company's stock, valued at approximately $

Janus Henderson Group PLC raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 1.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,965,546 shares of the company's stock after purchasing

Janux Therapeutics (NASDAQ:JANX) Shares Down 4.3%

Lord Abbett & CO. LLC bought a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 542,373 shares of the company's stock, valued at appro

Janux Therapeutics (NASDAQ:JANX) Stock Price Up 10.8%

Allspring Global Investments Holdings LLC trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 75.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor

Capstone Investment Advisors LLC acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 52,300 shares of the compa

Janux Therapeutics (NASDAQ:JANX) Shares Down 4.6%

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have a

Janux Therapeutics (NASDAQ:JANX) Shares Down 4%

Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $40.30

Janux Therapeutics (NASDAQ:JANX) Trading Up 4.2%